FDMT
NASDAQ4D Molecular Therapeutics Inc.
Price$12.15-0.50 (-3.99%)
01:30 PM07:45 PM
News · 26 weeks55+20%
2026-04-192026-10-11
Mix2190d
- Insider8(38%)
- Other7(33%)
- SEC Filings4(19%)
- Analyst2(10%)
Latest news
25 items- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 13, 2026, the compensation committee of the Company’s board of directors granted 13 new non-executive employees options to purchase an aggregate of 260,000 shares of the Company’s common stock and 157,600 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $12.36, which was the closing trading price on October 13, 2026
- INSIDERSEC Form 4 filed by 4D Molecular Therapeutics Inc.4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- PR4DMT to Host Investor Day on October 21, 2026Company to share insights on the advancing clinical profile and commercial vision for 4D-150Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C. Awh, MD, FASRS; Dr. David Eichenbaum, MD, FASRS; and Dr. Sara J. Haug, MD, PhD, will join 4DMT leadership to offer perspective on transforming the treatment paradigm in VEGF-driven retinal diseasesLive event will take place in New York City on October 21, 2026 at 10:30am ET EMERYVILLE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment parad
- SECSEC Form 8-K filed by 4D Molecular Therapeutics Inc.8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- PR4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating 4D-150 in a treatment-naïve DME populationUpdated 2-year data from SPECTRA Part 1 clinical trial in DME continue to demonstrate a favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential
- INSIDERChief Legal Officer Bizily Scott exercised 1,635 shares at a strike of $4.14 and sold $22,318 worth of shares (1,635 units at $13.65) as part of a pre-agreed trading plan (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDEROfficer Kirn David sold $811,004 worth of shares (58,333 units at $13.90) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 767,486 units (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- ANALYST4D Molecular Therapeutics upgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald upgraded 4D Molecular Therapeutics from Neutral to Overweight and set a new price target of $20.00
- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter int
- INSIDERChief Legal Officer Bizily Scott exercised 584 shares at a strike of $6.49 and sold $8,176 worth of shares (584 units at $14.00) as part of a pre-agreed trading plan (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- PR4DMT to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September: Wells Fargo 2026 Healthcare Conference: Wednesday, September 9, 20262026 Cantor Global Healthcare Conference: Thursday, September 10, 2026; Fireside chat at 10:20 a.m. ETMorgan Stanley 24th Annual Global Healthcare Conference: Monday, September 14, 2026; Fir
- INSIDEROfficer Kirn David exercised 50,000 shares at a strike of $4.14 and sold $1,088,273 worth of shares (69,076 units at $15.75) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 825,819 units (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERChief Legal Officer Bizily Scott exercised 3,270 shares at a strike of $4.14 and sold $39,567 worth of shares (3,270 units at $12.10) as part of a pre-agreed trading plan (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 11, 2026, the compensation committee of the Company’s board of directors granted five new non-executive employees 35,200 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into em
- SECSEC Form 10-Q filed by 4D Molecular Therapeutics Inc.10-Q - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- SEC4D Molecular Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- PR4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesCompleted enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027Presented positive 2-year data from 4D-150 PRISM Phase 2b at ASRS, highlighting long-term continuous treatment effect and ongoing favorable safety profilePlan to initiate a 4D-150 DME Phase 3 in Q3 2026Company to host an Investor Day on October 21, 2026, in New York CityEntered into a strategic credit facility agreement with Hercules Capital, Inc. for up to $200 million, initial draw of $20 million$431 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028 EMERYVILLE, Calif., A
- INSIDEROfficer Kirn David sold $274,596 worth of shares (26,842 units at $10.23) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 844,895 units (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDEROfficer Kirn David sold $124,722 worth of shares (12,415 units at $10.05) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 871,737 units (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- ANALYSTB. Riley Securities initiated coverage on 4D Molecular Therapeutics with a new price targetB. Riley Securities initiated coverage of 4D Molecular Therapeutics with a rating of Buy and set a new price target of $37.00
- SECSEC Form 8-K filed by 4D Molecular Therapeutics Inc.8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- PR4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD PopulationAfter a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular d
- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 14, 2026, the compensation committee of the Company’s board of directors granted six new non-executive employees 37,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into emplo
- INSIDEROfficer Kirn David sold $737,410 worth of shares (58,333 units at $12.64) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 884,152 units (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERChief Legal Officer Bizily Scott sold $91,924 worth of shares (6,566 units at $14.00) as part of a pre-agreed trading plan and exercised 6,566 shares at a strike of $6.20 (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
FDMT FAQ
7 questionsWhat does 4D Molecular Therapeutics Inc. do?
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment...Where does FDMT stock trade?
4D Molecular Therapeutics Inc. (FDMT) is listed on NASDAQ.What sector and industry is FDMT in?
4D Molecular Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did 4D Molecular Therapeutics Inc. go public?
4D Molecular Therapeutics Inc. (FDMT) completed its IPO in 2020.What are analysts saying about FDMT?
4D Molecular Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $2000.00 price target on 2026-09-14.What companies are similar to FDMT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare FDMT side-by-side with any of them on Quantisnow.How can I track FDMT on Quantisnow?
Quantisnow aggregates 4D Molecular Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FDMT to receive live email and push alerts on every new disclosure.